Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Primary Open Angle Glaucoma, Pseudoexfol...
Phase NA
Enrollment 196
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: surgery — 2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study

Primary Outcomes

  • Best Corrected Distance Visual Acuity at 1 Week (Week 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-20
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 196 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Dr. Herbert Reitsamer
Principal Investigators:
  • Herbert Reitsamer, MD (STUDY_CHAIR) - Paracelsus Medical University Salzburg/ Salzburger Landeskliniken
Contact Information
Study Contact:
Markus Lenzhofer, MD PhD
+43 5 7255
m.lenzhofer@salk.at
Herbert Reitsamer, MD
+43 5 7255
h.reitsamer@salk.at
Markus Lenzhofer, MD PhD
+43 5 7255
m.lenzhofer@salk.at
Dept. Ophthalmology and Optometry Paracelsus Medical University
Interventions
  • Device: surgery — 2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
Study Locations (1 sites)
Dept. Ophthalmology and Optometry Paracelsus Medical University, Salzburg, 5020 Austria
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of open angle glaucoma (Primary open angle glaucoma, Pseudoexfoliation glaucoma, Pigmentary dispersion glaucoma) 2. Clinically eligible for both surgeries (Trabeculectomy and XEN) on the discretion of the surgeon (area of healthy, free and mobile conjunctiva in the superior nasal target quadrant) 3. VA logMAR ≤ 1 (VA dec ≥ 0.1) 4. Trabecular meshwork must be visible (with Shaffer angle grade \> 1 in the target quadrant) 5. Age 18 years or older 6. Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent Exclusion Criteria: 1. Clinical significant cataract 2. Subject has had prior cataract surgery in study eye ≤ 1 months (count to operation) 3. Subject has had prior (incisional) glaucoma surgery (XEN, trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.). Prior iridotomy is acceptable. 4. Phacic Angle Closure Glaucoma 5. Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders 6. Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) 7. Anterior chamber intraocular lens 8. Vitreous present in the anterior chamber 9. Presence of intraocular silicone oil 10. History of corneal surgery, corneal opacities, or corneal disease 11. Impaired episcleral venous drainage (e.g. Sturge-Weber or nanophthalmos) 12. History of dermatologic keloid formation 13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, or other ophthalmic disease or disorder that could confound study results 14. Known or suspected allergy or sensitivity to drugs required for the surgical procedure or any of the device components (e.g., porcine products or glutaraldehyde), 15. Pregnant or nursing women
Conditions Bone Fracture, Glucose, High Blood, Insu...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatment. Many of these survivors experience adverse effects such as decreased bone mineral density, derangement of metabolic markers (fat, glucose, insulin) and increased blood pressure. Increasing risk of bone fracture and cardiometabolic disease (eg. diabetes mellitus type 2). The purpose of this study is to identify mechanisms behind cardiometabolic changes that may be connected to the (neo-)adjuvant treatment. On top of this we hope to indentify potential biological markers that can help prevent development of metabolic disease. We will be recruiting 120 post-menopausal women age 50-70 with early breast cancer and 1-2 times a year for 5 years examine bone mineral density, body composition, glucose and fat metabolism and nerve damage. A questionnaire will be used to collect information on diet, physical activity and quality of life. Derudover anvendes spørgeskemaer til at indsamle information vedrørende. This new knowledge will help clinicians start adequate preventive measures to help patients avoid cardiometabolic disease secondary to cancer treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Bone Mineral Density (1-5 years)
  • Metabolic syndrome (1-5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-12-17
Completion: 2026-11
Eligibility
Age: 50 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Principal Investigators:
  • Peter Schwarz, Prof, MD (PRINCIPAL_INVESTIGATOR) - Copenhagen University Hospital, Rigshospitalet
Contact Information
Study Contact:
Kristian Buch, cand.med.
29434376
buch.kristian@gmail.com
Kristian Buch, MD
29434376
kristian.buch@regionh.dk
Rigshospitalet
Interventions
N/A
Study Locations (1 sites)
Rigshospitalet, Copenhagen, Danmark 2100 Denmark
Eligibility Criteria
Inclusion Criteria: * Postmenopausal * Breast cancer stage I-III * Eligible to receive (neo-)adjuvant chemotherapy/other antineoplastic treatment Exclusion Criteria: * Prior malignancy * Metabolic disease (diabetes mellitus etc)
Conditions Type 2 Diabetes Mellitus (T2DM), Type 2 ...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Type 2 diabetes is diagnosed based on the results of a fasting blood glucose test and medication history. (Investigators plan to conduct follow-up examinations at intervals of one to two years.)
  • Hypertension is diagnosed based on the results of blood pressure measurement and medication history. (Investigators plan to conduct follow-up examinations at intervals of one to two years. plan to conduct follow-up examinations at intervals of one to two years.)
  • Dyslipidemia is diagnosed based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines. (Investigators plan to conduct follow-up examinations at intervals of one to two years. plan to conduct follow-up examinations at intervals of one to two years.)
  • Metabolic syndrome is diagnosed based on the Joint Interim Statement published in Circulation. 2009 Oct 20;120(16):1640-5. (Investigators plan to conduct follow-up examinations at intervals of one to two years. plan to conduct follow-up examinations at intervals of one to two years.)
  • Hyperuricemia is defined based on fasting serum uric acid levels and the use of oral medication. (Investigators plan to conduct follow-up examinations at intervals of one to two years. plan to conduct follow-up examinations at intervals of one to two years.)
  • Low eGFR was define based on the Modification of Diet in Renal Disease study equation for Japanese. (Investigators plan to conduct follow-up examinations at intervals of one to two years. plan to conduct follow-up examinations at intervals of one to two years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-01
Completion: 2050-03-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Osaka Metropolitan University
Collaborators: The Ministry of Education, Culture, Sports, Science and Technology, Japan
Principal Investigators:
  • Tomoshige Hayashi, MD, PhD (PRINCIPAL_INVESTIGATOR) - Osaka Metropolitan University
Contact Information
Study Contact:
Tomoshige Hayashi, MD, PhD
81-6-6645-3751
thayashi@omu.ac.jp
Kyoko Sato, MD, PhD
81-6-6645-3751
ksato@omu.ac.jp
Yonezo Hikita, MD, PhD
ocespart2@gmail.com
The Ohtori Health Promotion Center
Interventions
N/A
Study Locations (1 sites)
The Ohtori Health Promotion Center, Sakai, Osaka 5938324 Japan
Eligibility Criteria
Inclusion Criteria: \- Exclusion Criteria: * Women who may be pregnant
Conditions Valvular Heart Disease Stenosis and Regu...
Phase Not Applicable
Enrollment 590
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing clinically indicated transthoracic echocardiography (TTE). Participants undergo standard 12-lead ECG acquisition together with ECG recordings obtained using portable or wearable single-, 3-, and 6-lead devices. Established AI-ECG models will be evaluated for the detection of heart failure, pulmonary hypertension and valvular heart disease using TTE as the clinical reference standard, with performance compared across ECG acquisition modalities within the same prospective cohort. AI-ECG predictions are generated offline and are not provided to treating clinicians or used to alter clinical care. The study will also compare AI-ECG performance with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and evaluate the diagnostic performance of a combined AI-ECG and NT-proBNP approach. The study aims to recruit 590 participants across six NHS hospital sites. A prespecified subgroup of 203 participants will undergo dedicated venous blood sampling for NT-proBNP; eligible same-day NT-proBNP measurements obtained as part of routine clinical care will also be included where available.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Traditional 12-lead Electrocardiogram — A study-specific standard 12-lead ECG recording will be obtained with the participant in a semi-reclined position. A 10-second ECG will be acquired and pseudonymised for subsequent offline AI-ECG analysis. AI-ECG outputs will not be used to inform or alter clinical care.
  • Other: Apple Watch Series 4 Single-lead Electrocardiogram — A 30-second single-lead ECG will be recorded using an Apple Watch Series 4. The watch will be worn on the participant's left wrist and the participant will place their right index finger on the Digital Crown during recording. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram — A 30-second 3-lead ECG will be recorded using the Eko CORE 500 digital stethoscope with the participant seated. The device will be positioned over the upper left parasternal region. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram — Two 30-second ECG recordings will be obtained using the AliveCor KardiaMobile 6L device: a single-lead recording with the participant's thumbs placed on the upper electrodes, followed by a 6-lead recording with the thumbs on the upper electrodes and the lower electrode in contact with the left knee or ankle. Recordings will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide — A single 10 mL venous blood sample will be collected from the prespecified subgroup of 203 participants for measurement of serum NT-proBNP. Samples will be analysed by the relevant hospital clinical biochemistry laboratory and disposed of after testing. Eligible same-day NT-proBNP measurements obtained as part of routine NHS care may also be included without an additional blood sample. NT-proBNP results collected for the study will not be used to alter clinical care.

Primary Outcomes

  • AI-ECG model classification performance for detection of structural heart disease (Single study visit on the day of clinically indicated TTE (approximately 30-35 minutes); diagnostic performance calculated following completion of data collection.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-04
Completion: 2027-08-02
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 590 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Imperial College London
Contact Information
Study Contact:
Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA
+44 02075943614
a.el-medany24@imperial.ac.uk
Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA
+44 02075943614
a.el-medany24@imperial.ac.uk
Bristol Royal Infirmary
Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA
+44 02075943614
a.el-medany24@imperial.ac.uk
Southmead Hospital
Interventions
  • Other: Traditional 12-lead Electrocardiogram — A study-specific standard 12-lead ECG recording will be obtained with the participant in a semi-reclined position. A 10-second ECG will be acquired and pseudonymised for subsequent offline AI-ECG analysis. AI-ECG outputs will not be used to inform or alter clinical care.
  • Other: Apple Watch Series 4 Single-lead Electrocardiogram — A 30-second single-lead ECG will be recorded using an Apple Watch Series 4. The watch will be worn on the participant's left wrist and the participant will place their right index finger on the Digital Crown during recording. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram — A 30-second 3-lead ECG will be recorded using the Eko CORE 500 digital stethoscope with the participant seated. The device will be positioned over the upper left parasternal region. The ECG will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram — Two 30-second ECG recordings will be obtained using the AliveCor KardiaMobile 6L device: a single-lead recording with the participant's thumbs placed on the upper electrodes, followed by a 6-lead recording with the thumbs on the upper electrodes and the lower electrode in contact with the left knee or ankle. Recordings will be used for subsequent offline AI-ECG analysis and will not inform clinical care.
  • Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide — A single 10 mL venous blood sample will be collected from the prespecified subgroup of 203 participants for measurement of serum NT-proBNP. Samples will be analysed by the relevant hospital clinical biochemistry laboratory and disposed of after testing. Eligible same-day NT-proBNP measurements obtained as part of routine NHS care may also be included without an additional blood sample. NT-proBNP results collected for the study will not be used to alter clinical care.
Study Locations (6 sites)
Bristol Royal Infirmary, Bristol, United Kingdom
Southmead Hospital, Bristol, United Kingdom
Chelsea and Westminster Hospital, London, United Kingdom
Hammersmith Hospital, London, United Kingdom
St Mary's Hospital, London, United Kingdom
West Middlesex University Hospital, London, United Kingdom
Eligibility Criteria
Inclusion Criteria * Patients awaiting a transthoracic echocardiogram (TTE) based on clinical grounds as part of their standard care * Age 18-90 years * Able to provide informed consent Exclusion Criteria * Severe arrhythmia or unstable cardiovascular disease * Known severe structural heart disease, defined as any of the following: severe left ventricular systolic dysfunction (LVEF ≤35%); severe valvular heart disease according to current British Society of Echocardiography criteria; high echocardiographic probability of pulmonary hypertension according to current British Society of Echocardiography criteria; or previous structural cardiac intervention, including valve repair, valve replacement/implantation, or surgical repair of a cardiac chamber or congenital structural abnormality * Cardiac implantable electronic device in situ, including a permanent pacemaker or implantable cardioverter defibrillator * Current or recent involvement in another research study

Arterial Stiffness and Blood Pressure

NCT06495710
Recruiting
Conditions Hypertension, Vascular Stiffness, Aging
Phase NA
Enrollment 228
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension is a common and treatable disorder that remains the leading preventable cause of heart disease. Blood pressure treatment relies mainly on upper arm blood pressure readings and ignores blood vessel physiology and underlying individual genetic information. Older Veterans with hypertension are less likely to be treated to goal blood pressure because there are conflicting recommendations for what constitutes "optimal" in older adults. The investigators have developed a novel way to non-invasively assess the components of blood vessel stiffness that is related to blood pressure (load-dependent stiffness). This project will generate new knowledge about how different blood pressure treatment goals (intensive vs standard) impact different components of arterial stiffness and if these differences can be explained through genetic analysis. Results from this project will offer the VA an updated blueprint for personalizing blood pressure care in older adults, ultimately improving cardiovascular health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Blood pressure treatment algorithm — Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.

Primary Outcomes

  • Load-dependent arterial stiffness measured with pulse wave velocity (m/s) (12 months)
  • Structural arterial stiffness measured with pulse wave velocity (m/s) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2028-12-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 228 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Collaborators: VA Tennessee Valley Health Care System, Birmingham, Alabama VA Medical Center, The Lundquist Institute, University of Wisconsin, Madison
Principal Investigators:
  • Adam Gepner (PRINCIPAL_INVESTIGATOR) - William S. Middleton Memorial Veterans Hospital, Madison, WI
Contact Information
Study Contact:
Adam Gepner
(608) 256-1901
adam.gepner@va.gov
Nicole Lohr, MD
205-934-9166
Birmingham VA Medical Center, Birmingham, AL
Adam Gepner
608-256-1901
adam.gepner@va.gov
William S. Middleton Memorial Veterans Hospital, Madison, WI
Interventions
  • Other: Blood pressure treatment algorithm — Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
Study Locations (3 sites)
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama 35233-1927 United States
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee 37212-2637 United States
William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin 53705-2254 United States
Eligibility Criteria
Inclusion Criteria: * Male and female participants from VA VISN 7, 9, and 12 will be eligible to participate if they are over age 60 years and have a diagnosis of hypertension or take antihypertensive medications (up to 4). * Veterans will require documented SBP readings on 2 or more office visits that are 140 mmHg or average home blood pressure readings 135 mmHg to be eligible for the trial. * Participants must be willing to be randomized to intensive or standard blood pressure treatment and have blood pressure medications adjusted per the study protocol. * They must be willing to undergo tonometric evaluation of arterial stiffness, and carotid artery ultrasound. Exclusion Criteria: * Participants who have an indication for a specific BP lowering medication that is not included in the study protocol or a known secondary cause of hypertension will be excluded. * Patients will be excluded if they have: * a standing SBP \<110 mmHg * past history of a recent CVD event in the past 12 months (i.e., coronary artery disease event/intervention, congestive heart failure exacerbation or heart failure hospitalization, atrial fibrillation, or peripheral arterial disease intervention) * a class I indication for betablocker use including atrial arrhythmias * left-ventricular systolic function \<50%, \>moderate aortic stenosis * history of stroke * chronic kidney disease (eGFR\<30 mL/min/m2) or proteinuria in excess of 1 gram/day or polycystic kidney disease * active cancer (other than untreated, non-metastatic prostate cancer and non-melanoma skin cancer) * hypoxemic pulmonary disease * active rheumatologic or connective tissue diseases (i.e., systemic lupus erythematosus, rheumatoid arthritis, etc.) * human immunodeficiency virus * illness with any infectious etiology or fever \>38°C (i.e., upper respiratory illness, gastrointestinal illness, etc.) * hospitalization for any reason within the prior 4 weeks * Participants will be excluded if arm circumference is too large/small to allow accurate blood pressure recordings * The investigators will also exclude those with factors that may limit adherence to the study interventions or follow-up including active substance abuse, plans to move outside the study catchment areas within 12 months or a history of poor medication adherence or clinic no-shows
Conditions Hypertension, Sleep Disorder, Healthy
Phase Not Applicable
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The aims of this study are to determine the types and severity of previously undiagnosed sleep deficiencies in otherwise healthy Somali Americans, apply a research framework to define psychosocial, behavioral, environmental, and biological mechanisms mediating sleep deficiencies in Somali Americans, and examine the relationship between sleep deficiencies and increased blood pressure in Somali Americans.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: 24 hour blood pressure (BP) monitoring — 24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
  • Diagnostic Test: Polysomnography — Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.

Primary Outcomes

  • Undiagnosed sleep deficiency-short sleep (1 night sleep study, approximately 8-9 hours)
  • Undiagnosed sleep deficiency-insomnia (1 night sleep study, approximately 8-9 hours)
  • Undiagnosed sleep deficiency-obstructive sleep apnea (OSA) (1 night sleep study, approximately 8-9 hours)
  • Disrupted sleep (1 night sleep study, approximately 8-9 hours)
  • Blood pressure (BP) during wakefulness (Day 2)
  • Blood pressure (BP) during sleep (Day 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-15
Completion: 2028-10
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Virend Somers, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Somers CPL Lab
507-422-3499
CPLSOMALI@mayo.edu
Virend Somers, MD
Mayo Clinic in Rochester
Interventions
  • Diagnostic Test: 24 hour blood pressure (BP) monitoring — 24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
  • Diagnostic Test: Polysomnography — Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Subjects diagnosed with no known history of hypertension, diabetes, or sleep disorders. * Self-identify as Somali. * Adult males and females who are older than 18 years of age. Exclusion Criteria: * Anyone under 18 years or over 70 years. * Positive pregnancy.
Conditions Cirrhosis, Splenectomy, Portal Vein Thro...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Apixaban 2.5 MG — If portal vein thrombosis occurs more than one year after laparoscopic splenectomy, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.

Primary Outcomes

  • Proportion of complete recanalization of portal vein thrombosis (Follow-up of 6 months or greater)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northern Jiangsu People's Hospital
Principal Investigators:
  • Dou-Sheng Bai (STUDY_CHAIR) - Clinical Medical College, Yangzhou University
Contact Information
Study Contact:
Guo-Qing Jiang
+8651487373382
jgqing2003@hotmail.com
Dou-Sheng Bai
+8651487373382
bdsno1@hotmail.com
Guo-Qing Jiang, MD
+8651487373382
jgqing2003@hotmail.com
Clinical Medical College
Interventions
  • Drug: Apixaban 2.5 MG — If portal vein thrombosis occurs more than one year after laparoscopic splenectomy, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.
Study Locations (1 sites)
Clinical Medical College, Yangzhou, Jiangsu 225001 China
Eligibility Criteria
Inclusion Criteria: 1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology. 2. Splenomegaly with secondary hypersplenism. 3. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery. 4. Underwent laparoscopic splenectomy at our center. 5. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3. 6. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3 7. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3. 8. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12. 9. Developed portal vein thrombosis after 12 months post-surgery. 10. Provided informed consent to participate in the study. Exclusion Criteria: 1. Hepatocellular carcinoma or any other malignancy. 2. Hypercoagulable state other than the liver disease related. 3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 4. Portal hypertension bleeding . 5. Child - Pugh C 6. Recent peptic ulcer disease 7. History of Hemorrhagic stroke 8. Pregnancy. 9. Uncontrolled Hypertension 10. Human immunodeficiency virus (HIV) infection
Conditions Hypertension, Resistant to Conventional ...
Phase NA
Enrollment 100
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Physical activity — Physical activity will carry out 3 times per week during 12 weeks for intervention arm

Primary Outcomes

  • Systolic arterial blood pressure assessed by 24-hours home blood pressure monitoring (To baseline at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2015-03-26
Completion: 2025-02-18
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AGIR à Dom
Collaborators: University Hospital, Grenoble
Principal Investigators:
  • Jean-Louis Pépin, Pr MD PhD (PRINCIPAL_INVESTIGATOR) - Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France
Contact Information
Study Contact:
Jean-Louis Pépin, Pr MD PhD
JPepin@chu-grenoble.fr
Sandrine Bouzon
sbouzon@chu-grenoble.fr
Simon Gakwaya
Simon.Gakwaya@criucpq.ulaval.ca
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
Interventions
  • Other: Physical activity — Physical activity will carry out 3 times per week during 12 weeks for intervention arm
Study Locations (5 sites)
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canada
Hopital Universitaire de Grenoble, La Tronche, 38700 France
Clinique Pasteur, Toulouse, 31300 France
Hopitaux Universitaires de Genève, Geneva, Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Eligibility Criteria
Inclusion Criteria: * Patient with an obstructive sleep apnea (apnea-hypopnea index \> or equal to 15) * Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents * Ambulatory patient Exclusion Criteria: * Acute hepatic failure, biliary cirrhosis, cholestasis * Acute hypertension (SBP\>= 180 mmHg and/or DBP \>= 110 mmHg) * Contraindication to CPAP treatment
Conditions Abortion, Habitual, Infertility Unexplai...
Phase PHASE1
Enrollment 14
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: autologous decidual-like NK cells — intrauterine infusion

Primary Outcomes

  • Improvement rate of NK cells (6 months after the first intrauterine infusion therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-02-13
Completion: 2027-12
Eligibility
Age: 22 Years – 40 Years
Sex: FEMALE
Volunteers: false
Enrollment: 14 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: The University of Science and Technology of China
Principal Investigators:
  • Yali Hu (PRINCIPAL_INVESTIGATOR) - The Affiliated Drum Tower Hospital of Nanjing University
  • Hui Zhu (PRINCIPAL_INVESTIGATOR) - The Affiliated Drum Tower Hospital of Nanjing University
Contact Information
Study Contact:
Yali Hu
86-025-83106666
glyyhuyali@163.com
Hui Zhu
86-025-83106666
zhuhui1231@126.com
Yali Hu
The Affiliated Drum Tower Hospital of Nanjing University
Interventions
  • Biological: autologous decidual-like NK cells — intrauterine infusion
Study Locations (1 sites)
The Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu 210006 China
Eligibility Criteria
Inclusion Criteria: * abnormal uterine NK cell function; * have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction; * have clear fertility desires; * normal ovarian function or with frozen embryos; * edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \>= 7mm; * 18kg/m\^2 \< Body mass index \< 30kg/m\^2; Exclusion Criteria: * using progesterone receptor modulator; * chromosomal karyotype abnormalities in one spouse; * severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium; * uncontrolled autoimmune diseases; * abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study; * history of pelvic malignant tumors; * currently participating in other clinical studies; * allergic to blood products.
Conditions Hypertension
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

New sustainable models of patient-focused and team-based care for patients with hypertension should be developed to achieve health improvements and cost-efficiency. The aim of this project is to evaluate new ways of sustainable hypertension (HT) management in primary care, starting with a pilot study at 2 Primary Health Care Centres (PHCCs). At intervention PHCCs cardiovascular risk is assessed with SCORE2 for all hypertension patients. The staff receives education on HT treatment and an easy-to-follow treatment protocol. Non-physicians lead patient education on HT in groups. Patients receive a home blood pressure (BP) monitor and communicate digitally with the assigned nurse on medication update, blood and urinary tests and follow up. The nurse consults with the physician if needed. Regular face to face visits with the physician are only scheduled for patients with high cardiovascular risk or end organ damage, otherwise for all patients if needed. At the control PHCs hypertension care continues as usual. All participants will be asked to complete questionnaires after 6 and 24 months. Outcomes are feasibility for the pilot study and the proportion of patients reaching BP target plus change in systolic BP, cardiovascular risk factors, patients´ and staff´s grade of satisfaction and knowledge, and health care costs for the main study, compared between intervention and control PHCCS. Results will help to establish sustainable models of treating HT patients in Primary Care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: New model of Hypertension Management — Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
  • Other: Control — Hypertension Management as usual

Primary Outcomes

  • Blood pressure change (6 months)
  • Blood pressure change (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2035-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Skane
Contact Information
Study Contact:
Miriam Pikkemaat, PhD
0738185293
miriam.pikkemaat@med.lu.se
Miriam Pikkemaat, PhD
Husensjö Primary Health Care Center
Interventions
  • Other: New model of Hypertension Management — Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
  • Other: Control — Hypertension Management as usual
Study Locations (1 sites)
Husensjö Primary Health Care Center, Helsingborg, Sweden
Eligibility Criteria
Inclusion Criteria: \- Adult patients with hypertension Exclusion Criteria: * secondary hypertension according to the medical records at the Primary Health Care Center * terminal illness * pregnancy-induced hypertension * cognitive impairment * impaired vision (not able to read measurements for the home BP measurements or communicate via "1177 direct" digitally) * psychotic disorder
Conditions Critical Illness, Cirrhosis, Liver
Phase Not Applicable
Enrollment 226
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to demonstrate the relationship between intra-abdominal hypertension (IAH) and abundant microaspirations in mechanically ventilated cirrhotic.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • abundant microaspiration (48 hours after inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-10-08
Completion: 2026-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 226 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Lille
Principal Investigators:
  • Saad Nseir, MD,PhD (PRINCIPAL_INVESTIGATOR) - University Hospital, Lille
Contact Information
Study Contact:
Saad Nseir, MD,PhD
0320444495
saadalla.nseir@chru-lille.fr
0320445962
Hop Claude Huriez Chu Lille
0320445962
Hop Salengro - Hopital B
Interventions
N/A
Study Locations (2 sites)
Hop Claude Huriez Chu Lille, Lille, 59037 France
Hop Salengro - Hopital B, Lille, 59037 France
Eligibility Criteria
Inclusion Criteria: * adult patients * Cirrhosis * intubation and mechanical ventilation Exclusion Criteria: * pregnancy * oliguric patients * impossibility to measure intravesical pressure
Conditions Hypertension, Postpartum Preeclampsia
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nifedipine and Enalapril — Nifedipine 60mg by mouth every twelve hours plus Enalapril 5mg by mouth every twelve hours
  • Drug: Nifedipine and Labetalol — Nifedipine 60mg by mouth every twelve hours plus Labetalol 200mg by mouth every twelve hours

Primary Outcomes

  • Composite postpartum hypertension treatment failure within 6 weeks postpartum (6-weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-10
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Cleveland Clinic
Principal Investigators:
  • Amol Malshe, M.D. (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Amol Malshe, M.D.
216 903-9646
malshea@ccf.org
Amol Malshe
216-903-9646
malshea@ccf.org
Cleveland Clinic
Interventions
  • Drug: Nifedipine and Enalapril — Nifedipine 60mg by mouth every twelve hours plus Enalapril 5mg by mouth every twelve hours
  • Drug: Nifedipine and Labetalol — Nifedipine 60mg by mouth every twelve hours plus Labetalol 200mg by mouth every twelve hours
Study Locations (1 sites)
Cleveland Clinic, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria: * Postpartum women aged 18 years or older * Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features) * Taking Nifedipine 60 mg every 12 hours for blood pressure control * Persistently elevated blood pressure at/above 140/90 mmHg in a 24-hour time period or have one or more severe range blood pressure at/above 160/110 mmHg requiring a second antihypertensive medication * English speaking Exclusion Criteria: * Taking ≥2 antihypertensive agents during pregnancy * Heart block * Heart rate \<60 or \>120 beats per minute * Heart failure * Creatinine \>1.5 mg/dL * Renal artery stenosis * Active connective tissue disease * Cerebrovascular accident * Failed treatment or contraindications to nifedipine, enalapril or labetalol